IN2014DN11269A - - Google Patents

Info

Publication number
IN2014DN11269A
IN2014DN11269A IN11269DEN2014A IN2014DN11269A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A IN 11269DEN2014 A IN11269DEN2014 A IN 11269DEN2014A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A
Authority
IN
India
Prior art keywords
cell
malignant cancers
cell malignant
lymphoma
cancers include
Prior art date
Application number
Other languages
English (en)
Inventor
Francesco Bertoni
Paola Bonetti
Original Assignee
Oncoethix Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Sa filed Critical Oncoethix Sa
Publication of IN2014DN11269A publication Critical patent/IN2014DN11269A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN11269DEN2014 2012-06-25 2013-06-25 IN2014DN11269A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US201261670918P 2012-07-12 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
IN2014DN11269A true IN2014DN11269A (es) 2015-10-09

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11269DEN2014 IN2014DN11269A (es) 2012-06-25 2013-06-25

Country Status (12)

Country Link
US (1) US20140018353A1 (es)
EP (1) EP2863923B1 (es)
JP (1) JP6265979B2 (es)
KR (1) KR20150045423A (es)
CN (1) CN105050605A (es)
AU (1) AU2013283378B2 (es)
BR (1) BR112014032105A2 (es)
CA (1) CA2877434A1 (es)
IN (1) IN2014DN11269A (es)
MX (1) MX2014015986A (es)
RU (1) RU2659171C2 (es)
WO (1) WO2014001356A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2802608A4 (en) 2012-01-12 2015-08-05 Univ Yale COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015014998A1 (en) * 2013-08-01 2015-02-05 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
KR20160037201A (ko) * 2013-08-06 2016-04-05 온코에틱스 게엠베하 Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
JP2016538310A (ja) 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MY180775A (en) 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
KR20160145833A (ko) 2014-05-02 2016-12-20 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
US20170095484A1 (en) * 2014-05-02 2017-04-06 Oncoethix Gmbh Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
BR112016026046A8 (pt) 2014-05-08 2021-07-20 Oncoethix Gmbh uso de compostos de tienotriazolodiazepina
BR112016029012A2 (pt) 2014-06-13 2017-08-22 Oncoethix Gmbh método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
KR20170037670A (ko) * 2014-08-19 2017-04-04 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
KR101675984B1 (ko) * 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
EP4234554A3 (en) 2016-06-20 2023-12-27 Incyte Corporation Crystalline solid forms of a bet inhibitor
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
AU2019251223A1 (en) 2018-04-13 2020-11-26 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
PE20221582A1 (es) 2019-12-19 2022-10-06 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661284A1 (en) 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
ES2182108T3 (es) * 1996-09-13 2003-03-01 Mitsubishi Pharma Corp Compuestos de tienotriazolodiazepina y usos medicinales de los mismos.
WO2009084693A1 (ja) * 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
HUE031073T2 (en) * 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
US10071129B2 (en) * 2011-08-30 2018-09-11 Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. Method for identifying bromodomain inhibitors

Also Published As

Publication number Publication date
AU2013283378A1 (en) 2015-01-29
CN105050605A (zh) 2015-11-11
KR20150045423A (ko) 2015-04-28
RU2659171C2 (ru) 2018-06-28
RU2015101106A (ru) 2016-08-10
JP6265979B2 (ja) 2018-01-24
CA2877434A1 (en) 2014-01-03
EP2863923B1 (en) 2019-05-08
WO2014001356A1 (en) 2014-01-03
US20140018353A1 (en) 2014-01-16
BR112014032105A2 (pt) 2017-08-01
MX2014015986A (es) 2016-02-11
EP2863923A1 (en) 2015-04-29
AU2013283378B2 (en) 2017-07-13
JP2015531747A (ja) 2015-11-05

Similar Documents

Publication Publication Date Title
IN2014DN11269A (es)
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
NZ631144A (en) Compositions and methods for transmucosal absorption
MX2014009219A (es) Compuestos de purinona como inhibidores de quinasas.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
AU2011328009A8 (en) Compounds and methods for treating pain
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
MX2013010770A (es) Tratamiento de tumores solidos.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2014013090A (es) Derivados de pirrolotriazinona.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MD4538C1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.
CL2011002812A1 (es) Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
MX2013006184A (es) Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.
WO2012125871A3 (en) Aconitine compounds, compositions, uses, and preparation thereof
IN2015KN00676A (es)
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia